As the first litigation firm in New York for file lawsuits for Benicar injuries, we wanted to let you know that the New York Times in the Sunday Magazine section, February 16, 2014, ran a story on Benicar enteropathy. This was in their weekly column on difficult to diagnose medical cases. A 70 year old woman had presented to a Connecticut hospital with a history of uncontrollable diarrhea, with dehydration and weight loss. Initially the attending doctor could not figure out the cause. The way the column works, the Times had posted this medical mystery on line and asked readers to guess the diagnosis. A veterinary student did-it was due to Benicar!
The workup in the hospital had eliminated celiac disease, which we know is often confused with Benicar-induced gastric problems. At rounds the next morning, a pharmacist in the hospital, recalled reading about the Benicar warning issues by the FDA. He googled that to the attending. This led to stopping the drug and the patient getting better.
This pattern is precisely what our clients have experienced! We believe that most of these cases have excellent merit: the manufacturer failed to warn of this risk, even though the Mayo Clinic had sounded an alarm based on 22 cases they had seen at their hospital. We are presently placing our cases into suit in New Jersey where we have jurisdiction over the primary marketer of the drug, Daiichi Sankyo, and also Forest Labs, which had a co-marketing agreement.
